Integra LifeSciences Holdings (IART) 1996年年度报告「NASDAQ」.pdf

1、Integra LIfeScIenceS OvervIewvISIOnTo establish Integra LifeSciences Corporation as the industry leader in meeting the demand for a wide range of implantable,absorbable tissue regeneration and other pharmacological products that target and control cell behavior within the patients body.MISSIOnIntegr

2、a LifeSciences Corporation is dedicated to the acquisition,discovery and development of synergistic technologies for creating and marketing cost-effective,off-the-shelf,biosmart,absorbable products designed to target and control cell behavior.Clinically,these products are implanted to regenerate spe

3、cific body tissues and organs,or to cure or prevent a variety of diseases and age-associated conditions.1996 accOMPLISHMentS Achieved record sales and revenues.Received marketing approval from the United States Food and Drug Administration for INTEGRA Artificial Skin Dermal Regeneration Template for

4、 replacing severely burned skin.Named one of the years“most notable breakthrough devices”approved for marketing by the FDA in 1996.Became the first company to reach the market with a commercially manufactured,cost-effective permanent regenerative skin replacement system for severe burns.Completed a$

5、35 million public offering to support marketing efforts,clinical and preclinical studies,research and development programs to enhance our expanding product pipeline.Successfully completed worldwide training of over 600 surgeons in the use of INTEGRA Artificial Skin.Established ongoing exploration of

6、 expanded uses for INTEGRA Artificial Skin in plastic and reconstructive surgery,chronic wounds,and less severe burns.Successfully applied tissue regeneration technologies to cartilage,nerve and cardiovascular graft development programs.Launched commercial scale manufacturing of the Companys FDA ins